Cabaletta Bio, a clinical-stage biotech company focused on autoimmune disease therapies, announced a $150 million underwritten offering of 51.7 million common shares at $2.90 each. The funds will support the development and launch of their targeted cell therapies, including their lead investigational therapy, rese-cel. The offering includes participation from existing and new investors such as Bain Capital Life Sciences and Eli Lilly. The transaction is expected to close around May 5, 2026, pending customary conditions.
Cuprina Holdings shares surged 111.84% intraday following FDA 510(k) clearance for its MEDIFLY Maggots wound care product, the first maggot debridement therapy using Lucilia cuprina species approved in the U.S. The product treats non-healing necrotic...
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign featuring a series of vibrant summer events including the 50th Sun Life Hong Kong International Dragon Boat Festival, Pixar Summer Fest, and a major football event with top Euro...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign, featuring festivals, family attractions, sports events, and exclusive summer deals valid until August 31. Highlights include the 50th Sun Life Hong Kong International Dragon Bo...
